Streetbeat News

Products Services

EYEN

NBY

NovaBay Pharmaceuticals and Eyenovia have announced a partnership to co-promote prescription ophthalmic products to U.S. eyecare professionals. This collaboration aims to leverage the strengths of both companies in the eyecare market.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:08 am

NCNA

NuCana's stock price increased following the announcement that the company has been granted a US Patent for 'Phosphoramidate Derivatives For Use In The Treatment Of Cancer; Especially In The Treatment Where The Patient Shows Resistance.'

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:05 am

IONS

Ionis Pharmaceuticals, Inc. announced positive results from a Phase 2 study of ION224, a treatment for metabolic dysfunction-associated steatohepatitis (MASH), meeting primary and important secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

SLN

Silence Therapeutics plc (Nasdaq: SLN) announced positive 36-week data from the ALPACAR-360 phase 2 study of zerlasiran in subjects with high Lp(a) levels, a key risk factor for cardiovascular disease. Zerlasiran aims to lower Lp(a) production, potentially reducing the risk of atherosclerotic cardiovascular disease events.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:01 am

PEPG

PepGen announced that it has received U.S. FDA Orphan Drug and Rare Pediatric Disease designations for PGN-EDO51, aimed at treating Duchenne Muscular Dystrophy. These designations can provide certain benefits, including tax credits and eligibility for seven years of market exclusivity upon approval.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:01 am

FLOKIUSD

Cryptocurrency analyst Rekt Capital suggests FLOKI could reach new highs if it successfully retests two critical resistance levels at $0.000021 and $0.0000625, transforming them into support levels. This analysis comes amid FLOKI's recent token burns, reducing its circulating supply, and a spike in social dominance. Another analyst, Inmortal, also expressed optimism for FLOKI's potential rise, comparing it to the recent surge in PEPE. Currently, FLOKI is trading up 6.46% at $0.0002771.

Portfolio Pulse from Mehab Qureshi

March 13, 2024 | 11:00 am

SPOT

Spotify has announced the rollout of music videos in beta to Premium users in select markets. This new feature aims to enhance the user experience by integrating music videos, potentially increasing user engagement and time spent on the platform.

Portfolio Pulse from Charles Gross

March 13, 2024 | 10:55 am

DLTR

LEN

QQQ

S

SPY

TSLA

WSM

US stock futures indicate a flat open after a relief rally, with caution prevailing on Wall Street. Bitcoin surpasses $73K, while gold declines. Analysts stress the need for robust earnings to justify market strength, highlighting high S&P 500 valuations in a higher interest rate environment. SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ ETF (QQQ) show slight premarket movements. Tesla, Dollar Tree, Williams-Sonoma, SentinelOne, and Lennar are in focus due to stock performance and upcoming earnings.

Portfolio Pulse from Shanthi Rexaline

March 13, 2024 | 10:49 am

AMZN

LLY

Eli Lilly is collaborating with Amazon's Pharmacy Unit to facilitate the delivery of drug prescriptions through its direct-to-consumer service, LillyDirect, as reported by Reuters.

Portfolio Pulse from Charles Gross

March 13, 2024 | 10:11 am

CYBN

Cybin announced that it has received FDA Breakthrough Therapy Designation for its novel psychedelic molecule, CYB003, aimed at treating Major Depressive Disorder (MDD). Additionally, the company shared positive four-month durability data for CYB003 in MDD, indicating sustained efficacy over time.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 10:01 am